TRCT
CNSP icon

Tower Research Capital (TRC)’s CNS Pharmaceuticals CNSP Stock Holding History

Tower Research Capital (TRC)’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.13K Buy
+1,310
New +$5.43K ﹤0.01% 4361
2025
Q3 		– Sell
-562
Closed -$5.56K – 5264
2025
Q2 		$5.56K Buy
562
+136
+32% +$1.7K ﹤0.01% 4173
2025
Q1 		$6.95K Buy
+426
New +$20.8K ﹤0.01% 3998
2024
Q4 		– Sell
-27
Closed -$2.13K – 5725
2024
Q3 		$2.13K Buy
+27
New +$7.75K ﹤0.01% 5046
2024
Q2 		– Hold
0
– – – 5419
2024
Q1 		– Hold
0
– – – 5037
2023
Q4 		– Hold
0
– – – 4888
2023
Q3 		– Hold
0
– – – 4724
2023
Q2 		– Hold
0
– – – 4952
2023
Q1 		– Hold
0
– – – 4060
2022
Q4 		– Hold
0
– – – 3795
2022
Q3 		– Hold
0
– – – 4995
2022
Q2 		– Hold
0
– – – 4662
2022
Q1 		– Hold
0
– – – 4288
2021
Q4 		– Hold
0
– – – 4539

Other funds holding CNSP

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Tower Research Capital (TRC)'s CNSP Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in CNS Pharmaceuticals (CNSP) in Q1 2026: 1,310 shares worth $3.13K. The stake represents ﹤0.01% of the portfolio and ranks #4361 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in CNSP as recently as Q2 2025.

Tower Research Capital (TRC) first reported a position in CNSP in Q3 2024 and has held it in 4 quarters since. The position peaked at $6.95K in Q1 2025. 12 funds tracked by Wall St. Rank hold CNSP as of Q1 2026.

  • Tower Research Capital (TRC) held 1,310 shares of CNS Pharmaceuticals worth $3.13K as of Q1 2026.
  • CNS Pharmaceuticals was a new Tower Research Capital (TRC) position in Q1 2026.
  • CNS Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4361 holding.
  • Tower Research Capital (TRC) first reported a position in CNS Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • Tower Research Capital (TRC)'s CNS Pharmaceuticals position peaked at $6.95K in Q1 2025.
  • 12 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.